Abacus Life, Inc. (NASDAQ:ABL - Free Report) - Research analysts at Northland Capmk issued their Q1 2025 earnings per share (EPS) estimates for Abacus Life in a note issued to investors on Monday, November 25th. Northland Capmk analyst M. Grondahl anticipates that the company will post earnings of $0.15 per share for the quarter. Northland Capmk currently has a "Strong-Buy" rating on the stock. The consensus estimate for Abacus Life's current full-year earnings is $0.64 per share. Northland Capmk also issued estimates for Abacus Life's Q2 2025 earnings at $0.18 EPS, Q3 2025 earnings at $0.21 EPS, Q4 2025 earnings at $0.24 EPS and FY2025 earnings at $0.78 EPS.
Other research analysts also recently issued reports about the stock. B. Riley Financial reiterated a "buy" rating and issued a $16.00 price target on shares of Abacus Life in a research report on Friday, August 30th. Northland Securities assumed coverage on Abacus Life in a report on Thursday, October 24th. They issued an "outperform" rating and a $13.50 target price on the stock. Piper Sandler reissued an "overweight" rating and set a $13.00 price target (up previously from $12.00) on shares of Abacus Life in a report on Friday, November 8th. B. Riley raised their price objective on Abacus Life from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Monday. Finally, TD Cowen started coverage on Abacus Life in a research note on Wednesday, August 7th. They set a "buy" rating and a $14.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Abacus Life presently has a consensus rating of "Buy" and a consensus price target of $14.70.
View Our Latest Report on Abacus Life
Abacus Life Stock Performance
Shares of NASDAQ:ABL traded up $0.26 during trading on Thursday, hitting $8.08. The company's stock had a trading volume of 489,376 shares, compared to its average volume of 82,572. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.29 and a quick ratio of 1.29. The firm has a market cap of $603.17 million, a price-to-earnings ratio of -44.89 and a beta of 0.15. The company has a 50-day moving average of $9.17 and a 200-day moving average of $9.74. Abacus Life has a 12 month low of $6.56 and a 12 month high of $13.25.
Abacus Life (NASDAQ:ABL - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.06. The company had revenue of $28.15 million for the quarter, compared to the consensus estimate of $26.08 million. Abacus Life had a positive return on equity of 12.88% and a negative net margin of 11.65%. During the same quarter in the prior year, the company earned $0.01 earnings per share.
Hedge Funds Weigh In On Abacus Life
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABL. Renaissance Technologies LLC purchased a new position in shares of Abacus Life in the second quarter valued at $106,000. Levin Capital Strategies L.P. bought a new position in Abacus Life during the second quarter valued at $130,000. Richard W. Paul & Associates LLC grew its stake in shares of Abacus Life by 4.8% in the 2nd quarter. Richard W. Paul & Associates LLC now owns 30,448 shares of the company's stock worth $263,000 after buying an additional 1,401 shares in the last quarter. Quarry LP purchased a new stake in shares of Abacus Life during the 2nd quarter valued at about $318,000. Finally, Sei Investments Co. purchased a new position in Abacus Life in the second quarter worth about $418,000.
Insider Activity
In other Abacus Life news, insider Matthew Ganovsky sold 156,250 shares of Abacus Life stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $8.00, for a total value of $1,250,000.00. Following the sale, the insider now directly owns 10,847,047 shares in the company, valued at approximately $86,776,376. The trade was a 1.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jay J. Jackson sold 2,031,250 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $8.00, for a total transaction of $16,250,000.00. Following the transaction, the chief executive officer now directly owns 10,562,000 shares of the company's stock, valued at $84,496,000. This trade represents a 16.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 79.20% of the company's stock.
About Abacus Life
(
Get Free Report)
Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.
Featured Stories
Before you consider Abacus Life, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abacus Life wasn't on the list.
While Abacus Life currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
